Top

Published in:

Open Access 01-12-2024 | Lung Cancer | Research

Genomic features of lung cancer patients in Indonesia’s national cancer center

Authors: Arif Riswahyudi Hanafi, Muhammad Alfin Hanif, Mariska T.G. Pangaribuan, Wily Pandu Ariawan, Noorwati Sutandyo, Sri Agustini Kurniawati, Lyana Setiawan, Dian Cahyanti, Farilaila Rayhani, Priscillia Imelda

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Introduction

Advances in molecular biology bring advantages to lung cancer management. Moreover, high-throughput molecular tests are currently useful for revealing genetic variations among lung cancer patients. We investigated the genomics profile of the lung cancer patients at the National Cancer Centre of Indonesia.

Methods

A retrospective study enrolled 627 tissue biopsy samples using real time polymerase chain reaction (RT-PCR) and 80 circulating tumour DNA (ctDNA) liquid biopsy samples using next-generation sequencing (NGS) from lung cancer patients admitted to the Dharmais Cancer Hospital from January 2018 to December 2022. Data were obtained from medical records. Data statistically analysed with p < 0.05 is considered significant.

Result

The EGFR test results revealed by RT-PCR were wild type (51.5%), single variant (38.8%), double variant (8.3%), and triple variant (1.4%), with 18.66% L85R, 18.22% Ex19del, and 11.08% L861Q variant. Liquid biopsy ctDNA using NGS showed only 2.5% EGFR wild type, 62.5% single variant and 35% co-variant, with EGFR/TP53 and EGFR/PIK3CA as the highest.

Conclusion

EGFR variants are the most found in our centre. Liquid biopsy with ctDNA using NGS examination could detect broad variants and co-variants that will influence the treatment planning.

Global Cancer Observatory (gco.iacr.fr) [Internet]. Lyon: International Agency for Research of Cancer; 2022. Cancer today pie chart: Estimated number of new cases in 2020 worldwide, both sexes, all ages. Available from: Cancer Today (iarc.fr). Accessed on August 22, 2023.

World Health Organization. Indonesia [Internet]. World Health Organization; 2021. p1–2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf. Accessed on August 22, 2023.

Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801–11. https://doi.org/10.1016/j.humimm.2021.02.012.CrossRefPubMed

Sabour L, Sabour M, Ghorbian S. Clinical applications of next-generation sequencing in Cancer diagnosis. Pathol Oncol Res. 2017;23(2):225–34. https://doi.org/10.1007/s12253-016-0124-z.CrossRefPubMed

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.PubMedPubMedCentral

Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48–51.PubMedPubMedCentral

Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 2010;134(1):66–72. https://doi.org/10.5858/2008-0586-RAR1.1.CrossRefPubMed

Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060. https://doi.org/10.1136/esmoopen-2016-000060.CrossRefPubMedPubMedCentral

Zhao J, Han Y, Li J, Chai R, Bai C. Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer. Oncol Lett. 2019;17(3):3233–40. https://doi.org/10.3892/ol.2019.10012.CrossRefPubMedPubMedCentral

10.

Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. https://doi.org/10.1200/JCO.2012.45.2011.CrossRefPubMedPubMedCentral

11.

Singh AP, Li S, Cheng H. Circulating DNA in EGFR-mutated lung cancer. Ann Transl Med. 2017;5(18):379. https://doi.org/10.21037/atm.2017.07.10.CrossRefPubMedPubMedCentral

12.

Lung Cancer Statistics| How Common is Lung Cancer?| American Cancer Society [Internet]. Available from: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed on October 8, 2023.

13.

Mitsudomi T, Tan D, Yang JC, Ahn MJ, Batra U, Cho BC, Cornelio G, Lim T, Mok T, Prabhash K, Reungwetwattana T, Ren SX, Singh N, Toyooka S, Wu YL, Yang PC, Yatabe Y. Expert Consensus recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. J Thorac Oncol. 2023;18(4):436–46. https://doi.org/10.1016/j.jtho.2022.10.021.CrossRefPubMed

14.

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2012;15(5):299–304. https://doi.org/10.3779/j.issn.1009-3419.2012.05.09. Chinese.CrossRefPubMed

15.

Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the selection of patients with Lung Cancer for Treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(9):911–9. https://doi.org/10.1200/JCO.2017.76.7293.CrossRefPubMed

16.

Melosky B, Kambartel K, Häntschel M, Bennetts M, Nickens DJ, Brinkmann J, Kayser A, Moran M, Cappuzzo F. Worldwide Prevalence of epidermal growth factor receptor mutations in Non-small Cell Lung Cancer: a Meta-analysis. Mol Diagn Ther. 2022;26(1):7–18. https://doi.org/10.1007/s40291-021-00563-1.CrossRefPubMed

17.

Kosasih AS, Hanafi AR, Sukartini N, Pangaribunan M, Hanif MA, Ariawan WPAP, et al. The role of Liquid Biopsy for detecting epidermal growth factor receptor (EGFR) variants in patients with Advanced Non-small Cell Lung Cancer (NSCLC)– a preliminary Study in Indonesian Population. Indonesian J Cancer. 2023;17(3):203. https://doi.org/10.33371/ijoc.v17i3.1061.CrossRef

18.

Hassanein SS, Ibrahim SA, Abdel-Mawgood AL. Cell behavior of Non-small Cell Lung Cancer is at EGFR and MicroRNAs hands. Int J Mol Sci. 2021;22(22):12496. https://doi.org/10.3390/ijms222212496.CrossRefPubMedPubMedCentral

19.

Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163–7. https://doi.org/10.1126/science.1101637.CrossRefPubMed

20.

Castellanos E, Feld E, Horn L. Driven by mutations: the Predictive Value of Mutation Subtype in EGFR-Mutated Non-small Cell Lung Cancer. J Thorac Oncol. 2017;12(4):612–23. https://doi.org/10.1016/j.jtho.2016.12.014.CrossRefPubMed

21.

John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol. 2022;76:102080. https://doi.org/10.1016/j.canep.2021.102080.CrossRefPubMed

22.

Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP. Chih-Hsin Yang J. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 2015;10(5):793–9. https://doi.org/10.1097/JTO.0000000000000504.CrossRefPubMed

23.

Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126–31. https://doi.org/10.1093/annonc/mdt418.CrossRefPubMed

24.

Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5–13. https://doi.org/10.3978/j.issn.2218-6751.2011.12.01.CrossRefPubMedPubMedCentral

25.

O’Leary C, Gasper H, Sahin KB, Tang M, Kulasinghe A, Adams MN, Richard DJ, O’Byrne KJ. Epidermal Growth Factor Receptor (EGFR)-Mutated non-small-cell Lung Cancer (NSCLC). Pharmaceuticals (Basel). 2020;13(10):273. https://doi.org/10.3390/ph13100273.CrossRefPubMed

26.

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62. https://doi.org/10.1097/JTO.0000000000000033.CrossRefPubMedPubMedCentral

27.

Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302–16. https://doi.org/10.21037/tlcr.2019.04.12.CrossRefPubMedPubMedCentral

28.

Lam DC, Liam CK, Andarini S, Park S, Tan DSW, Singh N, Jang SH, Vardhanabhuti V, Ramos AB, Nakayama T, Nhung NV, Ashizawa K, Chang YC, Tscheikuna J, Van CC, Chan WY, Lai YH, Yang PC. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023;18(10):1303–22. Epub 2023 Jun 28. PMID: 37390982.CrossRefPubMed

29.

Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R, Kallel N, Ben Kridis-Rejeb W, Sallemi-Boudawara T, Khanfir A, Yangui I, Daoud J, Mokdad-Gargouri R. Predominance of the Rare EGFR Mutation p.L861Q in Tunisian patients with Non-small Cell Lung Carcinoma. Genes (Basel). 2022;13(8):1499. https://doi.org/10.3390/genes13081499.CrossRefPubMed

30.

Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277(2):301–8. https://doi.org/10.1111/j.1742-4658.2009.07448.x.CrossRefPubMed

31.

Hines AM, Patruni S, Kataria N, Boyd J, Seetharamu N, King DA. A case report of EGFR L861Q variant in synchronous de novo small cell and non-small cell lung cancer: molecular interrogation identifies origin and potential options for targeted therapy. Precis Cancer Med. 2023;6. https://doi.org/10.21037/pcm-22-67.

32.

Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006;66(16):8163–71. https://doi.org/10.1158/0008-5472.CAN-06-0453.CrossRefPubMed

33.

Kancha RK, Peschel C, Duyster J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol. 2011;6(2):387–92. https://doi.org/10.1097/JTO.0b013e3182021f3e.CrossRefPubMed

34.

Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–21. https://doi.org/10.1158/1078-0432.CCR-10-3408.CrossRefPubMed

35.

Choong WK, Sung TY. Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. iScience. 2021;24(6):102522. https://doi.org/10.1016/j.isci.2021.102522.CrossRefPubMedPubMedCentral

36.

Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O’Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR mutation type influence patient-reported outcomes in patients with Advanced EGFR mutation-positive non-small-cell Lung Cancer? Analysis of two large, phase III studies comparing afatinib with chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018;11(1):131–41. https://doi.org/10.1007/s40271-017-0287-z.CrossRefPubMed

37.

Jiang W, Cheng H, Yu L, Zhang J, Wang Y, Liang Y, Lou F, Wang H, Cao S. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer. Cancer Med. 2023;12(6):6649–58. https://doi.org/10.1002/cam4.5447.CrossRefPubMed

38.

Simarro J, Pérez-Simó G, Mancheño N, Ansotegui E, Muñoz-Núñez CF, Gómez-Codina J, Juan Ó, Palanca S. Impact of Molecular Testing using next-generation sequencing in the Clinical Management of patients with Non-small Cell Lung Cancer in a Public Healthcare Hospital. Cancers (Basel). 2023;15(6):1705. https://doi.org/10.3390/cancers15061705.CrossRefPubMed

39.

Saleh MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, Ulmer B, Wolf J, Buettner R. Comprehensive analysis of TP53 and KEAP1 mutations and their impact on Survival in localized- and Advanced-Stage NSCLC. J Thorac Oncol. 2022;17(1):76–88. https://doi.org/10.1016/j.jtho.2021.08.764.CrossRefPubMed

40.

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017;111:23–9. https://doi.org/10.1016/j.lungcan.2017.06.014.CrossRefPubMed

41.

Machado-Rugolo J, Baldavira CM, Prieto TG, Olivieri EHR, Fabro AT, Rainho CA, Castelli EC, Ribolla PEM, Ab’Saber AM, Takagaki T, Nagai MA, Capelozzi VL. Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. Braz J Med Biol Res. 2023;56:e12488. https://doi.org/10.1590/1414-431X2023e12488.CrossRefPubMedPubMedCentral

42.

Ferrara MG, Belluomini L, Smimmo A, Sposito M, Avancini A, Giannarelli D, Milella M, Pilotto S, Bria E. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2023;184:103929. https://doi.org/10.1016/j.critrevonc.2023.103929.CrossRefPubMed

43.

Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103(5):1475–9. https://doi.org/10.1073/pnas.0510857103.CrossRefPubMedPubMedCentral

44.

Daher S, Zer A, Tschernichovsky R, Yacobi R, Barshack I, Tsabari S, Rottenberg Y, Zick A, Gottfried T, Lobachov A, Marom EM, Urban D, Saad A, Gantz-Sorotsky H, Onn A, Bar J. Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. Lung Cancer. 2023;178:229–36. https://doi.org/10.1016/j.lungcan.2023.02.023.CrossRefPubMed

45.

Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A. Impact of concurrent PIK3CA mutations on response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung cancers and on prognosis in Oncogene-Driven Lung Adenocarcinomas. J Thorac Oncol. 2015;10(12):1713–9. https://doi.org/10.1097/JTO.0000000000000671.CrossRefPubMedPubMedCentral

46.

Pązik M, Michalska K, Żebrowska-Nawrocka M, Zawadzka I, Łochowski M, Balcerczak E. Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings. BMC Cancer. 2021;21(1):130. https://doi.org/10.1186/s12885-021-07858-w.CrossRefPubMedPubMedCentral

47.

Kodaz H. Frequency of RAS variants (KRAS, NRAS, HRAS) in human solid Cancer. Eurasian J Med Oncol. 2017;1(1):1–7. https://doi.org/10.14744/ejmo.2017.22931.CrossRef

48.

An SJ, Huang YS, Chen ZH, Han JF, Yang JJ, Zhou Q, Xie Z, Yang Y, Yan HH, Wu YL. Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy. Cancer Gene Ther. 2014;21(3):110–4. https://doi.org/10.1038/cgt.2014.5.CrossRefPubMed

49.

Cho BC, Loong HHF, Tsai CM, Teo MLP, Kim HR, Lim SM, Jain S, Olsen S, Park K. Genomic Landscape of Non-small Cell Lung Cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice. Curr Oncol. 2022;29(3):2154–64. https://doi.org/10.3390/curroncol29030174.CrossRefPubMedPubMedCentral

50.

Peng P, Lv G, Hu J, Wang K, Lv J, Guo G. Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. Ann Transl Med. 2021;9(16):1321. https://doi.org/10.21037/atm-21-3570.CrossRefPubMedPubMedCentral

51.

Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J, Wömpner C, Bitter E, Koleczko S, Abdulla DSY, Michels S, Fischer R, Riedel R, Weber JP, Westphal T, Gerigk U, Kern J, Kaminsky B, Randerath W, Kambartel KO, Merkelbach-Bruse S, Büttner R, Wolf J. Co-occurrence of targetable mutations in non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. Lung Cancer. 2020;144:40–8. https://doi.org/10.1016/j.lungcan.2020.04.020.CrossRefPubMed

52.

Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-Mutant Non-small Cell Lung Cancer: a review. Front Oncol. 2020;10:610923. https://doi.org/10.3389/fonc.2020.610923.CrossRefPubMedPubMedCentral

53.

Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295–308. https://doi.org/10.1038/nrc2109.CrossRefPubMed

54.

Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, Yokoyama T, Yano M, Fujii Y. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep. 2007;18(3):623–8.PubMed

55.

Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Genomic signature of driver genes identified by Target Next-Generation sequencing in Chinese Non-small Cell Lung Cancer. Oncologist. 2019;24(11):e1070–81. https://doi.org/10.1634/theoncologist.2018-0572.CrossRefPubMedPubMedCentral

56.

Su J, Zhong W, Zhang X, Huang Y, Yan H, Yang J, Dong Z, Xie Z, Zhou Q, Huang X, Lu D, Yan W, Wu YL. Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients. Oncotarget. 2017;8(67):111246–57. https://doi.org/10.18632/oncotarget.22768.CrossRefPubMedPubMedCentral

57.

Chen Y, Xu J, Zhang L, Song Y, Wen W, Lu J, Zhao Z, Kong W, Liu W, Guo A, Santarpia M, Yamada T, Cai X, Yu Z. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. Transl Lung Cancer Res. 2022;11(2):238–49. https://doi.org/10.21037/tlcr-22-48.CrossRefPubMedPubMedCentral

58.

Yu S, Sha H, Qin X, Chen Y, Li X, Shi M, Feng J. EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. 2020;39(13):2643–57. https://doi.org/10.1038/s41388-020-1182-y.CrossRefPubMed

59.

Van der Wekken AJ, Stigt JA, A’t Hart. N. A novel EGFR mutation in exon 19 showed stable disease after TKI treatment. J Thorac Oncol. 2012;7(8):e8. https://doi.org/10.1097/JTO.0b013e31825ccae8.CrossRefPubMed

60.

Xia P, Liu E, Li P, Li W, Jiang G. A case of primary resistance to Gefitinib due to Novel deletion-insertion mutation of EGFR exon 19 in NSCLC. J Thorac Oncol. 2019;14(6):e117–9. https://doi.org/10.1016/j.jtho.2019.01.033.CrossRefPubMed

61.

Peng X, Long X, Liu L, Zeng L, Yang H, Jiang W, Liao D, Li K, Wang J, Lizaso A, Mao X, Xu Q, Mansfield AS, Yang N, Zhang Y. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. Eur J Cancer. 2020;141:199–208. https://doi.org/10.1016/j.ejca.2020.10.005.CrossRefPubMed

Title: Genomic features of lung cancer patients in Indonesia’s national cancer center
Authors: Arif Riswahyudi Hanafi
Muhammad Alfin Hanif
Mariska T.G. Pangaribuan
Wily Pandu Ariawan
Noorwati Sutandyo
Sri Agustini Kurniawati
Lyana Setiawan
Dian Cahyanti
Farilaila Rayhani
Priscillia Imelda
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
SCLC
SCLC
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02851-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Comorbidity increases the risk of pulmonary tuberculosis: a nested case-control study using multi-source big data

Effects and long-term outcomes of endurance versus resistance training as an adjunct to standard medication in patients with stable COPD: a multicenter randomized trial

Study on predictive models for swallowing risk in patients with AECOPD

Construction and evaluation of neonatal respiratory failure risk prediction model for neonatal respiratory distress syndrome

Patient education needs in severe asthma, a pilot study

Continuous estimation of respiratory system compliance and airway resistance during pressure-controlled ventilation without end-inspiration occlusion

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials